Literature DB >> 27220658

Circulating serum irisin levels in obesity and type 2 diabetes mellitus.

Amira Shoukry1, Sally M Shalaby2, Shereen El-Arabi Bdeer3, Amira A Mahmoud1, Mayada M Mousa1, Ashraf Khalifa1.   

Abstract

Irisin is an exercise-regulated myokine inducing browning of white adipose tissue and has gained interest as a potential new strategy to combat obesity and its associated disorders, such as type 2 diabetes mellitus (T2DM). The aim of this study is to evaluate the circulating serum irisin levels in obesity and T2DM and also to elucidate possible relationships between serum irisin levels with anthropometric and metabolic parameters of obesity and T2DM. One hundred fifty newly diagnosed T2DM patients as well as 150 nondiabetic control subjects were enrolled in this study. Nondiabetic controls were then stratified according to their body mass index (BMI) into three subgroups; lean, overweight, and obese. Serum irisin levels were evaluated by enzyme-linked immunosorbent assay. Serum irisin levels were significantly decreased in T2DM patients compared with nondiabetic controls. Obese nondiabetic controls had significantly higher serum irisin levels compared with lean nondiabetic controls. In both nondiabetic controls and T2DM patients, serum irisin was significantly positively correlated with BMI (r = 0.985, P < 0.001 and r = 0.218, P = 0.007, respectively), fat mass (r = 0.959, P < 0.001 and r = 0.202, P = 0.013, respectively), fat-free mass (r = 0.606, P < 0.001 and r = 0.194, P = 0.017, respectively), fat-free mass index (r = 0.820, P < 0.001 and r = 0.179, P = 0.028, respectively), waist-to-hip ratio (r = 0.880, P < 0.001 and r = 0.194, P = 0.017, respectively), fasting insulin (r = 0.989, P < 0.001 and r = 0.207, P = 0.011, respectively), and HOMA-IR (r = 0.989, P < 0.001 and r = 0.185, P = 0.023, respectively), whereas; significantly negatively correlated with insulin sensitivity (r = -0.992, P < 0.001 and r = -0.187, P = 0.022, respectively). In this study, we demonstrated that circulating serum irisin levels were increased in obese nondiabetic subjects, while decreased in T2DM patients. Moreover, serum irisin levels were correlated with anthropometric and metabolic markers of obesity and T2DM.
© 2016 IUBMB Life, 68(7):544-556, 2016. © 2016 International Union of Biochemistry and Molecular Biology.

Entities:  

Keywords:  obesity; serum irisin; type 2 diabetes mellitus

Mesh:

Substances:

Year:  2016        PMID: 27220658     DOI: 10.1002/iub.1511

Source DB:  PubMed          Journal:  IUBMB Life        ISSN: 1521-6543            Impact factor:   3.885


  30 in total

Review 1.  Irisin in metabolic diseases.

Authors:  Stergios A Polyzos; Athanasios D Anastasilakis; Zoe A Efstathiadou; Polyzois Makras; Nikolaos Perakakis; Jannis Kountouras; Christos S Mantzoros
Journal:  Endocrine       Date:  2017-11-23       Impact factor: 3.633

2.  Eight-week exercise program improved the quality of life of Alzheimer's patients through functional, cognitive, and biochemical parameters.

Authors:  Fatih Kar; Yasemin Kavlak; Selda Yıldız; Pınar Yıldız; Ahmet Musmul; Sema Uslu
Journal:  Ir J Med Sci       Date:  2022-05-23       Impact factor: 1.568

3.  Serum Irisin Levels and Clinical Implication in Elderly Patients With Type 2 Diabetes Mellitus.

Authors:  Xianfa Xuan; Jincheng Lin; Yiqin Zhang; Lina Zhou; Liping Xu; Junlu Jia; Benhua Zhao; Zhiyang Lin; Qiong Zhu; Lianmeng Li; Ting Wu; Siyu Zhang; Hanxiang Jiang; Yuxin Wang
Journal:  J Clin Med Res       Date:  2020-08-15

4.  Serum Irisin, Adropin, and Preptin in Obese Patients 6 Months After Bariatric Surgery.

Authors:  M Glück; J Glück; M Wiewióra; B Rogala; J Piecuch
Journal:  Obes Surg       Date:  2019-10       Impact factor: 4.129

5.  Long-term GABA administration improves FNDC5, TFAM, and UCP3 mRNA expressions in the skeletal muscle and serum irisin levels in chronic type 2 diabetic rats.

Authors:  Farzaneh Yazdanimoghaddam; Maedeh Ghasemi; Hanif Teamparvar; Nepton Soltani; Mahmoud Aghaei; Hossein Rezazadeh; Fouzieh Zadhoush
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2022-02-02       Impact factor: 3.000

Review 6.  Metabolic Adaptation in Obesity and Type II Diabetes: Myokines, Adipokines and Hepatokines.

Authors:  Kyoung-Jin Oh; Da Som Lee; Won Kon Kim; Baek Soo Han; Sang Chul Lee; Kwang-Hee Bae
Journal:  Int J Mol Sci       Date:  2016-12-22       Impact factor: 5.923

7.  Serum irisin associates with breast cancer to spinal metastasis.

Authors:  Zheng-Ping Zhang; Xue-Fang Zhang; Hui Li; Tuan-Jiang Liu; Qin-Peng Zhao; Lin-Hong Huang; Zi-Jun Cao; Li-Min He; Ding-Jun Hao
Journal:  Medicine (Baltimore)       Date:  2018-04       Impact factor: 1.817

8.  The effects of aerobic, resistance, and combined exercises on the plasma irisin levels, HOMA-IR, and lipid profiles in women with metabolic syndrome: A randomized controlled trial.

Authors:  Aria Dianatinasab; Roghayeh Koroni; Mehrdad Bahramian; Zahra Bagheri-Hosseinabadi; Mojtaba Vaismoradi; Mohammad Fararouei; Sasan Amanat
Journal:  J Exerc Sci Fit       Date:  2020-06-20       Impact factor: 3.103

9.  Irisin, physical activity and fitness status in healthy humans: No association under resting conditions in a cross-sectional study.

Authors:  Nathalie Biniaminov; Susanne Bandt; Alexander Roth; Sascha Haertel; Rainer Neumann; Achim Bub
Journal:  PLoS One       Date:  2018-01-30       Impact factor: 3.240

Review 10.  Targeting Obesity and Diabetes to Treat Heart Failure with Preserved Ejection Fraction.

Authors:  Raffaele Altara; Mauro Giordano; Einar S Nordén; Alessandro Cataliotti; Mazen Kurdi; Saeed N Bajestani; George W Booz
Journal:  Front Endocrinol (Lausanne)       Date:  2017-07-17       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.